What this study adds?
Ropeginterferon alfa-2b is a novel pegylated interferon with superior pharmacokinetic parameters than the marketed pegylated interferon product, allowing biweekly injection.
Ropeginterferon alfa-2b has better safety profiles than the marketed pegylated interferon product.